晚期肺癌患者靶向药物治疗对其生命质量的影响

目的 观察晚期肺癌患者靶向药物治疗对其生命质量的影响.方法 选择我院2011年1月-2012年12月门诊或住院治疗的初治晚期非小细胞肺癌（non-small-cell lung cancer,NSCLC）表皮生长因子受体（epidermal growth factor receptor,EGFR）基因突变的95例,根据入选时间及随机数字表分为吉非替尼组49例和培美曲塞组46例.吉非替尼组予吉非替尼250 mg/d口服,每4周为1个治疗周期,直至出现疾病进展或不可耐受的毒性及不良反应而停止.培美曲塞组予培美曲塞500 mg/m2加入0.9％氯化钠注射液100 ml静脉滴注,每周期第1天用药,21 d为1个治疗周期,共治疗4个周期.治疗前及治疗后4周时根据欧洲癌症研究与治疗组织（EORTC）推荐的“肿瘤生命质量核心问卷（QLQ-C30）”进行评估并比较.结果 吉非替尼组治疗后QLQ-C30问卷中整体功能、特异症状模块（除便秘、腹泻外）各指标评分及整体生命质量评分与治疗前比较差异均有统计学意义（P ＜0.05,P＜0.01）;且治疗后吉非替尼组上述指标均明显优于培美曲塞组,差异亦均有统计学意义（P ＜0.05,P＜0.01）.结论 晚期肺癌患者接受吉非替尼靶向治疗期间生命质量较好.

Effect of Targeted Therapy on Quality of Life of Patients with Advanced Lung Cancer

Objective To observe the effect of targeted drug therapy on quality of life of patients with advanced non-small cell lung cancer （NSCLCs）.Methods Ninety five NSCLC patients with positively mutated epidemic growth factor receptor （EG-FR） treated in Shengjing Hospital of China Medical University between January 2011 and December 2012 were divided into the Gefitinib group （group A,n =49） and the Pemetrexed group （group B,n =46） according to entered date and random number table.Group A was treated with 250 mg/d Gefitinib po and the medication was stopped until the occurrence of tumor progression or unacceptable toxicity,and a treatment cycle was 4 weeks.While group B was treated with Pemetrexed 500 mg/m2 and 0.9％ sodium chloride injection 100 ml with injection on the first day of each cycle and for 4 cycles,and a treatment cycle was 21 d.Core quality of life questionnaire （QLQ-C30） of European Organization for Research on Treatment of Cancer （EORTC） were assessed and com pared before and four week after treatment.Results There were significant differences in allomeric function,scores of symptomspecific modules （exception for constipation and diarrhea） of QLQ-C30 scores in group A after treatment compared with those before treatment （P ＜ 0.05,P ＜ 0.01） ; and after treatment all the above scores in group A were significantly better than those in group B （P ＜0.05,P ＜0.01）.Conclusion Gefitinib targeted therapy can improve quality of life for patients with advanced NSCLC.